Harrow Health is trading 9.13% down at $36.98 after its August 10 second-quarter earnings release showed a larger-than-expected loss and slight revenue miss.
- Q2 revenue reached $70.7 million, while the EPS loss was $0.46; full-year revenue guidance remained $350 million-$365 million.
- VEVYE revenue increased approximately 40% sequentially, but investors appear focused on profitability and execution risks.